Headquartered in Nantes, France, OSE Immunotherapeutics S.A. is a biotechnology company dedicated to pioneering immunotherapies. Its research and development efforts are concentrated on modulating immune responses, specifically in the domains of immuno-oncology and autoimmune disorders. The company's diverse pipeline features several key candidates. Tedopi is currently in a pivotal Phase III study for non-small cell lung cancer, with ongoing Phase II investigations for pancreatic and ovarian cancers. CoVepiT is another notable candidate, a prophylactic vaccine designed to prevent SARS-CoV-2 infection. Additionally, BI 765063 is progressing through Phase I clinical trials for the treatment of various solid tumors. A particularly innovative offering is the BiCKI platform, a bispecific checkpoint inhibitor engineered to overcome primary and secondary cancer resistance mechanisms by simultaneously targeting PD-1 and other novel therapeutic pathways. Beyond its oncology focus, OSE's portfolio includes OSE-127, a humanized monoclonal antibody currently in Phase II development for managing ulcerative colitis and Sjögren's Syndrome. FR104, an investigational treatment for rheumatoid arthritis, is undergoing Phase I trials, and OSE-230, an agonist antibody targeting ChemR23, aims to address chronic inflammatory conditions. OSE Immunotherapeutics actively engages in strategic alliances and partnerships, notably with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA before officially adopting its current name in May 2016.
—
Headquartered in Nantes, France, OSE Immunotherapeutics S.A. is a biotechnology company dedicated to pioneering immunotherapies. Its research and development efforts are concentrated on modulating immune responses, specifically in the domains of immuno-oncology and autoimmune disorders. The company's diverse pipeline features several key candidates. Tedopi is currently in a pivotal Phase III study for non-small cell lung cancer, with ongoing Phase II investigations for pancreatic and ovarian cancers. CoVepiT is another notable candidate, a prophylactic vaccine designed to prevent SARS-CoV-2 infection. Additionally, BI 765063 is progressing through Phase I clinical trials for the treatment of various solid tumors. A particularly innovative offering is the BiCKI platform, a bispecific checkpoint inhibitor engineered to overcome primary and secondary cancer resistance mechanisms by simultaneously targeting PD-1 and other novel therapeutic pathways. Beyond its oncology focus, OSE's portfolio includes OSE-127, a humanized monoclonal antibody currently in Phase II development for managing ulcerative colitis and Sjögren's Syndrome. FR104, an investigational treatment for rheumatoid arthritis, is undergoing Phase I trials, and OSE-230, an agonist antibody targeting ChemR23, aims to address chronic inflammatory conditions. OSE Immunotherapeutics actively engages in strategic alliances and partnerships, notably with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA before officially adopting its current name in May 2016.
—
Daily adjusted close
Headquartered in Nantes, France, OSE Immunotherapeutics S.A. is a biotechnology company dedicated to pioneering immunotherapies. Its research and development efforts are concentrated on modulating immune responses, specifically in the domains of immuno-oncology and autoimmune disorders. The company's diverse pipeline features several key candidates. Tedopi is currently in a pivotal Phase III study for non-small cell lung cancer, with ongoing Phase II investigations for pancreatic and ovarian cancers. CoVepiT is another notable candidate, a prophylactic vaccine designed to prevent SARS-CoV-2 infection. Additionally, BI 765063 is progressing through Phase I clinical trials for the treatment of various solid tumors. A particularly innovative offering is the BiCKI platform, a bispecific checkpoint inhibitor engineered to overcome primary and secondary cancer resistance mechanisms by simultaneously targeting PD-1 and other novel therapeutic pathways. Beyond its oncology focus, OSE's portfolio includes OSE-127, a humanized monoclonal antibody currently in Phase II development for managing ulcerative colitis and Sjögren's Syndrome. FR104, an investigational treatment for rheumatoid arthritis, is undergoing Phase I trials, and OSE-230, an agonist antibody targeting ChemR23, aims to address chronic inflammatory conditions. OSE Immunotherapeutics actively engages in strategic alliances and partnerships, notably with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA before officially adopting its current name in May 2016.